{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:04:28Z","timestamp":1790190268972,"version":"4.1.0"},"reference-count":110,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:00:00Z","timestamp":1450396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Veterinary Sciences"],"abstract":"<jats:p>Feline immunodeficiency virus (FIV) is one of the most common infectious agents affecting cats worldwide .FIV and human immunodeficiency virus (HIV) share many properties: both are lifelong persistent lentiviruses that are similar genetically and morphologically and both viruses propagate in T-lymphocytes, macrophages, and neural cells. Experimentally infected cats have measurable immune suppression, which sometimes progresses to an acquired immunodeficiency syndrome. A transient initial state of infection is followed by a long latent stage with low virus replication and absence of clinical signs. In the terminal stage, both viruses can cause severe immunosuppression. Thus, FIV infection in cats has become an important natural model for studying HIV infection in humans, especially for evaluation of antiviral compounds. Of particular importance for chemotherapeutic studies is the close similarity between the reverse transcriptase (RT) of FIV and HIV, which results in high in vitro susceptibility of FIV to many RT-targeted antiviral compounds used in the treatment of HIV-infected patients. Thus, the aim of this article is to provide an up-to-date review of studies on antiviral treatment of FIV, focusing on commercially available compounds for human or animal use.<\/jats:p>","DOI":"10.3390\/vetsci2040456","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T10:15:04Z","timestamp":1450433704000},"page":"456-476","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus"],"prefix":"10.3390","volume":"2","author":[{"given":"Katrin","family":"Hartmann","sequence":"first","affiliation":[{"name":"Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Wooding","sequence":"additional","affiliation":[{"name":"Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mich\u00e8le","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jfms.2009.05.019","article-title":"Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in germany","volume":"11","author":"Gleich","year":"2009","journal-title":"J. Feline Med. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/vr.146.15.419","article-title":"Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus","volume":"146","author":"Addie","year":"2000","journal-title":"Vet. Rec."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jfms.2008.03.002","article-title":"2008 american association of feline practitioners\u2019 feline retrovirus management guidelines","volume":"10","author":"Levy","year":"2008","journal-title":"J. Feline Med. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1021\/jm00014a001","article-title":"Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections","volume":"38","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_6","unstructured":"Greene, C.E. (2012). Infectious Diseases of the Dog and Cat, Elsevier, Saunders. [4th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/mol.65.1.244","article-title":"Susceptibility of feline immunodeficiency virus\/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors","volume":"65","author":"Auwerx","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/v4050708","article-title":"Pharmacological inhibition of feline immunodeficiency virus (FIV)","volume":"4","author":"Mohammadi","year":"2012","journal-title":"Viruses"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2165\/11640830-000000000-00000","article-title":"NRTI backbone in HIV treatment: Will it remain relevant?","volume":"72","author":"Tressler","year":"2012","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-405880-4.00009-3","article-title":"The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS)","volume":"67","year":"2013","journal-title":"Adv. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1021\/jo01030a546","article-title":"Nucleosides. V. The monomesylates of 1-(2'-deoxy-b-d-lyxofuranosyl)thymine","volume":"29","author":"Horwitz","year":"1964","journal-title":"J. Org. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3'-azido-3'-deoxythymidine (BW a509u): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type iii\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/326430b0","article-title":"Azt given the green light for clinical treatment of AIDS","volume":"326","author":"Ezzell","year":"1987","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1128\/AAC.38.4.861","article-title":"Multiple-drug-resistant mutants of feline immunodeficiency virus selected with 2',3'-dideoxyinosine alone and in combination with 3'-azido-3'-deoxythymidine","volume":"38","author":"Gobert","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","first-page":"16","article-title":"AZT in the treatment of feline immunodeficiency virus infection: Part 1","volume":"23","author":"Hartmann","year":"1995","journal-title":"Feline Pract"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0166-3542(01)00190-5","article-title":"Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication","volume":"53","author":"Bisset","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.2460\/ajvr.2001.62.588","article-title":"In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants","volume":"62","author":"McBroom","year":"2001","journal-title":"Am. J. Vet. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1128\/jvi.65.1.308-312.1991","article-title":"Mutants of feline immunodeficiency virus resistant to 3\u2032-azido-3\u2032-deoxythymidine","volume":"65","author":"Remington","year":"1991","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/jvi.68.2.632-637.1994","article-title":"Rapid phenotypic reversion of zidovudine-resistant feline immunodeficiency virus without loss of drug-resistant reverse transcriptase","volume":"68","author":"Remington","year":"1994","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2460\/ajvr.75.3.273","article-title":"Antiviral efficacy of nine nucleoside reverse transcriptase inhibitors against feline immunodeficiency virus in feline peripheral blood mononuclear cells","volume":"75","author":"Schwartz","year":"2014","journal-title":"Am. J. Vet. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1128\/jvi.71.3.2357-2362.1997","article-title":"A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides","volume":"71","author":"Smith","year":"1997","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1128\/JVI.72.3.2335-2340.1998","article-title":"A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine","volume":"72","author":"Smith","year":"1998","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/34.4.589","article-title":"Susceptibility in cell culture of feline immunodeficiency virus to eighteen antiviral agents","volume":"34","author":"Smyth","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0166-3542(92)90075-G","article-title":"Anti-human immunodeficiency virus (HIV) agents are also potent and selective inhibitors of feline immunodeficiency virus (FIV)-induced cytopathic effect: Development of a new method for screening of anti-FIV substances in vitro","volume":"19","author":"Tochikura","year":"1992","journal-title":"Antivir. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/AAC.39.3.746","article-title":"(r-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection","volume":"39","author":"Vahlenkamp","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1128\/AAC.40.9.1983","article-title":"Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine","volume":"40","author":"Zhu","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/AAC.33.6.915","article-title":"Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome","volume":"33","author":"North","year":"1989","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","first-page":"13","article-title":"Azt in the treatment of feline immunodeficiency virus infection: Part 2","volume":"23","author":"Hartmann","year":"1995","journal-title":"Feline Pract."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1090-0233(98)80008-7","article-title":"Feline immunodeficiency virus infection: An overview","volume":"155","author":"Hartmann","year":"1998","journal-title":"Vet. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1016\/0006-2952(88)90655-7","article-title":"Initial studies on the cellular pharmacology of 3'-deoxythymidin-2'-ene (D4T): A potent and selective inhibitor of human immunodeficiency virus","volume":"37","author":"August","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","article-title":"Both 2\u2032,3\u2032-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro","volume":"142","author":"Baba","year":"1987","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S0026-895X(25)13752-8","article-title":"The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2\u2032,3\u2032-didehydro-2',3'-dideoxyribonucleosides: A comparison with their parental 2',3'-dideoxyribonucleosides","volume":"32","author":"Balzarini","year":"1987","journal-title":"Mol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1016\/0006-2952(87)90253-X","article-title":"Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus","volume":"36","author":"Lin","year":"1987","journal-title":"Biochem. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2009.10.006","article-title":"Early nucleoside reverse transcriptase inhibitors for the treatment of HIV: A brief history of stavudine (D4T) and its comparison with other dideoxynucleosides","volume":"85","author":"Martin","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0026-895X(25)09549-5","article-title":"Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine and its 5'-monophosphate triester prodrug SO324","volume":"50","author":"Balzarini","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000150121","article-title":"Testing of nucleoside analogues in cats infected with feline leukemia virus: A model","volume":"30","author":"Tavares","year":"1989","journal-title":"Intervirology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1073\/pnas.83.6.1911","article-title":"Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type iii\/lymphadenopathy-associated virus (HTLV-III\/LAV) by 2',3'-dideoxynucleosides","volume":"83","author":"Mitsuya","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1128\/AAC.40.4.953","article-title":"Selection and characterization of a mutant of feline immunodeficiency virus resistant to 2',3'-dideoxycytidine","volume":"40","author":"Medlin","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/brain\/awm148","article-title":"Didanosine causes sensory neuropathy in an HIV\/AIDS animal model: Impaired mitochondrial and neurotrophic factor gene expression","volume":"130","author":"Zhu","year":"2007","journal-title":"Brain: J. Neurol."},{"key":"ref_40","unstructured":"FDA Antiretroviral Drugs Used in the Treatment of Human Immunodeficiency Virus Infection, Available online: http:\/\/www.Fda.Gov\/forpatients\/illness\/HIVAIDS\/treatment\/ucm118915.Htm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0165-2427(01)00426-3","article-title":"Is AZT\/3TC therapy effective against FIV infection or immunopathogenesis?","volume":"85","author":"Arai","year":"2002","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ravichandran, S., Veerasamy, R., Raman, S., Krishnan, P.N., and Agraval, R.K. (2008). An overview on HIV-1 reverse transcriptase inhibitors. Dig. J. Nanomater. Biostruct., 171\u2013187.","DOI":"10.1016\/j.virusres.2008.01.003"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2009.09.014","article-title":"Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine","volume":"85","author":"Cihlar","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_44","first-page":"911","article-title":"Acyclic nucleoside phosphonates: Past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: The phosphonate bridge","volume":"73","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.41.3.611","article-title":"Antiretroviral activities of acyclic nucleoside phosphonates [9-(2-phosphonylmethoxyethyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, (R)-9-(2-phosphonylmethoxypropyl)adenine, and mdl 74,968] in cell cultures and murine sarcoma virus-infected newborn nmri mice","volume":"41","author":"Balzarini","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00002030-199101000-00003","article-title":"9-(2-phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in Rhesus monkeys","volume":"5","author":"Balzarini","year":"1991","journal-title":"AIDS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0165-2427(92)90129-E","article-title":"Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FELV seropositive cats with clinical symptoms","volume":"35","author":"Hartmann","year":"1992","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1073\/pnas.87.8.3087","article-title":"Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine","volume":"87","author":"Egberink","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.3390\/v4112684","article-title":"Clinical aspects of feline retroviruses: A review","volume":"4","author":"Hartmann","year":"2012","journal-title":"Viruses"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/00042560-199802010-00004","article-title":"Efficacy of the acyclic nucleoside phosphonates (S)-9-(3-fluoro-2-phosphonylmethoxypropyl)adenine (FPMPA) and 9-(2-phosphonylmethoxyethyl)adenine (PMEA) against feline immunodeficiency virus","volume":"17","author":"Hartmann","year":"1998","journal-title":"J. Acquir. Immune Deficiency Syndr. Hum. Retrovirol."},{"key":"ref_51","first-page":"671","article-title":"comparative investigation of the efficacy of two nucleocapsid analogs in FIV infected cats","volume":"25","author":"Kuffer","year":"1997","journal-title":"Tierarztliche Praxis Ausgabe K, Kleintiere\/Heimtiere"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0165-2427(92)90128-D","article-title":"Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction","volume":"35","author":"Philpott","year":"1992","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1939-1676.2012.00904.x","article-title":"Efficacy and adverse effects of the antiviral compound plerixafor in feline immunodeficiency virus-infected cats","volume":"26","author":"Hartmann","year":"2012","journal-title":"J. Vet. Intern. Med.\/Am. Coll. Vet. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/bbrc.1996.0234","article-title":"Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems","volume":"219","author":"Balzarini","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1110\/ps.072829007","article-title":"Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses","volume":"16","author":"Xia","year":"2007","journal-title":"Protein Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nsmb.2223","article-title":"HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism","volume":"19","author":"Das","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/mol.61.2.400","article-title":"Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: Role of the subunits in resistance\/sensitivity to non-nucleoside reverse transcriptase inhibitors","volume":"61","author":"Auwerx","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0090-4295(98)00544-5","article-title":"Suramin treatment in hormone- and chemotherapy-refractory prostate cancer","volume":"53","author":"Schulze","year":"1999","journal-title":"Urology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(85)90002-9","article-title":"Effects of suramin on HTLV-III\/LAV infection presenting as Kaposi\u2019s Sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo","volume":"2","author":"Broder","year":"1985","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3835(79)90017-X","article-title":"Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses","volume":"8","year":"1979","journal-title":"Cancer Lett."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.2460\/ajvr.1986.47.10.2230","article-title":"Effect of suramin on serum viral replication in feline leukemia virus-infected pet cats","volume":"47","author":"Cogan","year":"1986","journal-title":"Am. J. Vet. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V77.7.1442.1442","article-title":"Retrovirus-induced feline pure red blood cell aplasia: Pathogenesis and response to suramin","volume":"77","author":"Abkowitz","year":"1991","journal-title":"Blood"},{"key":"ref_63","first-page":"1100","article-title":"Suramin and the human adrenocortex: Results of experimental and clinical studies","volume":"110","author":"Dorfinger","year":"1991","journal-title":"Surgery"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1015666024386","article-title":"Suramin\u2019s development: What did we learn?","volume":"20","author":"Kaur","year":"2002","journal-title":"Investig. New Drugs"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1001\/archderm.1992.01680110085011","article-title":"Suramin-induced skin reactions","volume":"128","author":"Dawson","year":"1992","journal-title":"Arch. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/0002-9343(92)90329-A","article-title":"Mechanism of action of foscarnet against viral polymerases","volume":"92","author":"Crumpacker","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_67","first-page":"72","article-title":"Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection","volume":"19","author":"Wang","year":"2014","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_68","first-page":"936","article-title":"Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat","volume":"5","author":"Straw","year":"1992","journal-title":"J. Acquir. Immun. Defic. Syndr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0924-8579(95)00008-V","article-title":"Pharmacology and clinical use of foscarnet","volume":"5","author":"Gerard","year":"1995","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0272-0590(92)90204-U","article-title":"Hypocalcemia induced by foscarnet (Foscavir) infusion in dogs","volume":"18","author":"Ryrfeldt","year":"1992","journal-title":"Fundam. Appl. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.coviro.2014.04.011","article-title":"Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance","volume":"8","author":"Beaucourt","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2460\/ajvr.1978.39.08.1337","article-title":"Effect of orally administered ribavirin on experimental feline calicivirus infection in cats","volume":"39","author":"Povey","year":"1978","journal-title":"Am. J. Vet. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2885.1993.tb00177.x","article-title":"Toxicologic effects of ribavirin in cats","volume":"16","author":"Weiss","year":"1993","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/0034-5288(93)90076-R","article-title":"Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis","volume":"55","author":"Weiss","year":"1993","journal-title":"Res. Vet. Sci."},{"key":"ref_76","unstructured":"Greene, C.E. (1998). Infectious Diseases of the Dog and Cat, Elsevier Saunders. [2nd ed.]."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1128\/jvi.71.12.8999-9007.1997","article-title":"Utilization of chemokine receptors, orphan receptors, and herpesvirus-encoded receptors by diverse human and simian immunodeficiency viruses","volume":"71","author":"Rucker","year":"1997","journal-title":"J. Virol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/096876899294779","article-title":"The role of the chemokine receptor CXCR4 in infection with feline immunodeficiency virus","volume":"16","author":"Willett","year":"1999","journal-title":"Mol. Membr. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1128\/jvi.71.9.6407-6415.1997","article-title":"Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses","volume":"71","author":"Willett","year":"1997","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1074-5521(96)90126-X","article-title":"Chemokine receptors\u2014The new frontier for AIDS research","volume":"3","author":"Wells","year":"1996","journal-title":"Chem. Biol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/nm0198-072","article-title":"AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor","volume":"4","author":"Donzella","year":"1998","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1128\/JVI.73.8.6346-6352.1999","article-title":"Bicyclams, selective antagonists of the human chemokine receptor CXCR4, potently inhibit feline immunodeficiency virus replication","volume":"73","author":"Egberink","year":"1999","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0166-3542(97)00025-9","article-title":"Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin\/CXCR-4","volume":"35","author":"Schols","year":"1997","journal-title":"Antivir. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","article-title":"Mobilization of hematopoietic progenitor cells in healthy volunteers by amd3100, a CXCR4 antagonist","volume":"102","author":"Liles","year":"2003","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2174\/157016208785132527","article-title":"Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistent HIV-1","volume":"6","author":"Norelli","year":"2008","journal-title":"Curr. HIV Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1073\/pnas.95.3.939","article-title":"Analysis of the S3 and S3' subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1128\/JVI.78.9.4525-4532.2004","article-title":"Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3","volume":"78","author":"Lin","year":"2004","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2174\/157016207781023965","article-title":"HIV-1 integrase: From biology to chemotherapeutics","volume":"5","author":"Nicolaou","year":"2007","journal-title":"Curr. HIV Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jmr.970","article-title":"HIV-1 in alternative molecular recognition of DNA induced by raltegravir resistance mutations","volume":"22","author":"Mouscadet","year":"2009","journal-title":"J. Mol. Recognit."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.vetmic.2011.03.039","article-title":"Inhibition of feline leukemia virus replication by the integrase inhibitor raltegravir","volume":"152","author":"Cattori","year":"2011","journal-title":"Vet. Microbiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1099\/vir.0.039909-0","article-title":"Discovery of drugs that possess activity against feline leukemia virus","volume":"93","author":"Greggs","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1128\/JVI.03208-12","article-title":"Comprehensive in vitro analysis of simian retrovirus type 4 susceptibility to antiretroviral agents","volume":"87","author":"Togami","year":"2013","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.vetmic.2014.10.031","article-title":"Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection","volume":"175","author":"Boesch","year":"2015","journal-title":"Vet. Microbial."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.vetimm.2011.06.008","article-title":"Use of recombinant interferon omega in feline retrovirosis: From theory to practice","volume":"143","author":"Domenech","year":"2011","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1677::AID-CNCR13>3.0.CO;2-1","article-title":"Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: Final results of a phase I\u2013II study of the cancer biotherapy research group and the mid-atlantic oncology program","volume":"82","author":"Stark","year":"1998","journal-title":"Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.rvsc.2012.09.025","article-title":"Relevance of feline interferon omega for clinical improvement and reduction of concurrent viral excretion in retrovirus infected cats from a rescue shelter","volume":"94","author":"Gil","year":"2013","journal-title":"Res. Vet. Sci."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1099\/0022-1317-81-10-2341","article-title":"Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures","volume":"81","author":"Goodbourn","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/eji.200838311","article-title":"Anti-retroviral effects of type I IFN subtypes in vivo","volume":"39","author":"Gerlach","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/v1030545","article-title":"Effect of type-I interferon on retroviruses","volume":"1","author":"Collado","year":"2009","journal-title":"Viruses"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1128\/AAC.34.9.1749","article-title":"Alpha interferon (2\u03b2) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome","volume":"34","author":"Zeidner","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1099\/0022-1317-20-1-97","article-title":"Circulating interferon in rabbits after administration of human interferon by different routes","volume":"20","author":"Cantell","year":"1973","journal-title":"J. Gen. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/107999099313352","article-title":"Oral use of interferon","volume":"19","author":"Cummins","year":"1999","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_103","first-page":"64","article-title":"Efficacy of kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS)","volume":"67","author":"Koech","year":"1990","journal-title":"East. Afr. Med. J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/107999099313325","article-title":"Immunomodulation and therapeutic effects of the oral use of interferon-alpha: Mechanism of action","volume":"19","author":"Tompkins","year":"1999","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1089\/107999001317205169","article-title":"Feline immunodeficiency virus lacks sensitivity to the antiviral activity of feline ifn-gamma","volume":"21","author":"Tanabe","year":"2001","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.vetimm.2005.08.020","article-title":"Low-dose interferon-alpha treatment for feline immunodeficiency virus infection","volume":"109","author":"Pedretti","year":"2006","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_107","first-page":"477","article-title":"Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FELV)-infected and FELV\/feline immunodeficiency virus (FIV)-coinfected symptomatic cats","volume":"18","author":"Maynard","year":"2004","journal-title":"J. Vet. Intern. Med.\/Am. Coll. Vet. Intern. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rvsc.2013.11.007","article-title":"Oral recombinant feline interferon-omega as an alternative immune modulation therapy in FIV positive cats: Clinical and laboratory evaluation","volume":"96","author":"Gil","year":"2014","journal-title":"Res. Vet. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.rvsc.2015.02.008","article-title":"Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega","volume":"99","author":"Leal","year":"2015","journal-title":"Res. Vet. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jfms.2009.05.006","article-title":"Feline immunodeficiency. ABCD guidelines on prevention and management","volume":"11","author":"Hosie","year":"2009","journal-title":"J. Feline Med. Surg."}],"container-title":["Veterinary Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2306-7381\/2\/4\/456\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:54:18Z","timestamp":1760216058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2306-7381\/2\/4\/456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,18]]},"references-count":110,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,12]]}},"alternative-id":["vetsci2040456"],"URL":"https:\/\/doi.org\/10.3390\/vetsci2040456","relation":{},"ISSN":["2306-7381"],"issn-type":[{"value":"2306-7381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,18]]}}}